Analyst Ratings for Akebia Therapeutics (AKBA) [Buys]
AKBA Rating Summary
AKBA Price Target Summary
- Highest: $6.00 (H.C. Wainwright)
- Lowest: $4.00 (BTIG)
- Average: $4.67
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$4.67 (+240.6%)
* Over Last 12-Mos
Rating Score: 6.5 / 10
Percentile Rank: 69%
Avg. $ Target:
$4.67 (+240.6%)
* Over Last 12-Mos
Rating Score: 6.5 / 10
Percentile Rank: 69%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/29/2023 | BTIG | Julian Harrison | New Coverage | Buy (N/A) |
4.00 (N/A) |
0.96 (1.37) |
42.71% | Details |
| 8/28/2023 | H.C. Wainwright » Updated 4/1/2024 |
Ed Arce | Upgrade | Buy (Neutral) |
6.00 (5.00) |
1.15 (1.37) |
19.13% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
